Report on the developments of the National Immunisation Programme: national immunisation coverage increased slightly for the first time in five years National immunisation coverage has increased for the first time in five years, for almost all vaccinations. For children born in 2017, vaccination coverage against mumps, measles and rubella (MMR) increased by 0.7% to 93.6%.
Spread of tick-borne encephalitis virus in the Netherlands Every year about 1.5 million ticks bite someone in the Netherlands, especially between March and October. Most people will not get sick of that.
A decrease in the number of tuberculosis patients in the Netherlands In 2019, the number of people with tuberculosis (TB) in the Netherlands decreased to 759. This is 5 per cent less than in 2018, when 797 were reported.
A pregnant woman can protect her baby against whooping cough with 22-week vaccination From 16 December 2019, pregnant women in the Netherlands will be offered the 22-week vaccination. With this vaccination, a pregnant woman protects her child and herself against whooping cough.
A guide for the safe reuse of diaper and incontinence materials RIVM has developed a step-by-step plan for the safe reuse of diapers and incontinence material. This plan provides recyclers and licensing authorities with tools to carry out a risk assessment.
Emphasising safety and sustainability in circular design A stronger focus on safety, health and sustainability is needed in designing circular products. When basic resources are re-used in new products, health risks should be avoided.
Slightly more tuberculosis patients in the Netherlands The key figures of the National Institute for Public Health and the Environment (RIVM) show that in 2018 there were 806 TB patients in the Netherlands. This is 3 percent more than in 2017 (784).
Strong decline of tuberculosis in the Netherlands The number of tuberculosis (TB) patients in the Netherlands decreased considerably in 2017. From 887 patients in 2016 to 787 in 2017.
New test has no added value in Lyme disease of the central nervous system Active Lyme disease of the central nervous system cannot be detected with an ELISpot test.
Lyme disease costs EUR 20 million annually The societal costs of Lyme disease have been determined for the Netherlands for the first time. The disease appears to cost nearly EUR 20 million each year.